National Marrow Donor Program
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$25.6M
Doctors Paid
276
Transactions
5,232
2024 Total
$10.2M
Payment Breakdown by Category
Research$13.9M (54.2%)
Consulting$653,510 (2.5%)
Travel$594,712 (2.3%)
Food & Beverage$128,225 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.9M | 1,597 | 54.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10.4M | 1,413 | 40.4% |
| Consulting Fee | $653,510 | 280 | 2.5% |
| Travel and Lodging | $594,712 | 1,286 | 2.3% |
| Food and Beverage | $128,225 | 618 | 0.5% |
| Honoraria | $10,925 | 19 | 0.0% |
| Gift | $740.19 | 14 | 0.0% |
| Entertainment | $450.00 | 5 | 0.0% |
Payments by Type
Research
$13.9M
1,597 transactions
General
$11.8M
3,635 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies | $2.2M | 0 | 199 |
| A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001) | $2.2M | 0 | 44 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705) | $1.2M | 0 | 36 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant | $1.1M | 0 | 47 |
| MM CAR-T to Upgrade Response - Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide | $963,776 | 0 | 33 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hem | $867,564 | 0 | 42 |
| A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease | $592,581 | 0 | 35 |
| A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | $552,500 | 0 | 40 |
| Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases | $532,312 | 0 | 54 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | $514,465 | 0 | 119 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation | $480,687 | 0 | 195 |
| PROSPECTIVE OBSERVATIONAL STUDY OF THE IMMUNOGENICITY OF VACCINES FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT), ALLOGENEIC HCT, AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY | $345,396 | 0 | 188 |
| 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe | $212,325 | 0 | 46 |
| A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV SteroidRefractory Acute Graft-Versus-Host Disease (SR-aGVHD) | $188,165 | 0 | 20 |
| Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE) | $185,246 | 0 | 58 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | $166,193 | 0 | 24 |
| Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events | $160,735 | 0 | 47 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies | $152,088 | 0 | 16 |
| Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST | $150,012 | 0 | 15 |
| A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202) | $115,225 | 0 | 37 |
| MM CAR-T to Upgrade Response - Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenanc | $113,388 | 0 | 8 |
| Composite Health Assessment Risk Model (CHARM) for Older Adults | $110,186 | 0 | 42 |
| Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease | $97,491 | 0 | 38 |
| Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | $94,000 | 0 | 26 |
| Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors | $81,200 | 0 | 84 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant | $81,054 | 0 | 5 |
| A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies | $64,563 | 0 | 8 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant | $54,100 | 0 | 5 |
| Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST BMT CTN 1903 | $50,010 | 0 | 5 |
| Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704) | $49,051 | 0 | 21 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Hematology-Oncology | $211,757 | 33 | $6,417 |
| Hematology | $144,177 | 21 | $6,866 |
| Hematology & Oncology | $140,384 | 69 | $2,035 |
| Ophthalmology | $113,531 | 1 | $113,531 |
| Medical Oncology | $79,834 | 25 | $3,193 |
| Registered Nurse | $62,889 | 2 | $31,444 |
| Pediatrics | $62,553 | 22 | $2,843 |
| Internal Medicine | $59,973 | 54 | $1,111 |
| Anesthesiology | $56,672 | 2 | $28,336 |
| Emergency Medicine | $52,376 | 3 | $17,459 |
| Nurse Practitioner | $48,699 | 3 | $16,233 |
| Adult Health | $48,620 | 1 | $48,620 |
| Advanced Practice Midwife | $27,669 | 1 | $27,669 |
| Surgery | $26,677 | 2 | $13,339 |
| Otolaryngology | $12,765 | 1 | $12,765 |
| Nurse Anesthetist, Certified Registered | $12,000 | 1 | $12,000 |
| Oncology | $7,048 | 1 | $7,048 |
| Cardiovascular Disease | $5,682 | 1 | $5,682 |
| Student in an Organized Health Care Education/Training Program | $5,297 | 5 | $1,059 |
| Blood Banking & Transfusion Medicine | $3,213 | 4 | $803.21 |
| Family | $2,783 | 2 | $1,391 |
| Specialist | $2,520 | 3 | $839.98 |
| Trauma Surgery | $1,874 | 1 | $1,874 |
| Pediatric Allergy/Immunology | $1,800 | 1 | $1,800 |
| Children | $1,788 | 2 | $893.75 |
| Nephrology | $800.00 | 1 | $800.00 |
| Pediatric Emergency Medicine | $789.51 | 1 | $789.51 |
| Infectious Disease | $771.93 | 1 | $771.93 |
| Neonatal | $575.00 | 1 | $575.00 |
| Obstetrics & Gynecology | $575.00 | 1 | $575.00 |
| Allergy & Immunology | $510.87 | 1 | $510.87 |
| Family Medicine | $472.81 | 1 | $472.81 |
| Pediatric Endocrinology | $400.94 | 1 | $400.94 |
| Clinical Pathology/Laboratory Medicine | $356.55 | 2 | $178.28 |
| Critical Care Medicine | $319.12 | 1 | $319.12 |
| Acute Care | $300.00 | 1 | $300.00 |
| Hospitalist | $214.51 | 1 | $214.51 |
| Pediatric Infectious Diseases | $214.51 | 1 | $214.51 |
| Dermatology | $197.93 | 1 | $197.93 |
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Iskra Pusic, Md, MD | Medical Oncology | Saint Louis, MO | $3,191 | $0 |
| Dr. David Hall, M.d, M.D | Anesthesiology | Chattanooga, TN | $3,150 | $0 |
| Dr. Brian Shaffer, M.d, M.D | Internal Medicine | New York, NY | $3,149 | $0 |
| Omer Jamy | Hematology & Oncology | Birmingham, AL | $3,139 | $0 |
| Lori Muffly, M.d, M.D | Internal Medicine | Stanford, CA | $3,098 | $0 |
| Brian Mcclune, Do, DO | Hematology & Oncology | Salt Lake City, UT | $3,004 | $0 |
| Usama Gergis, Md, MD | Hematology & Oncology | Allentown, PA | $2,800 | $0 |
| Jonathan Lambird, M.d, M.D | Student in an Organized Health Care Education/Training Program | Winston Salem, NC | $2,797 | $0 |
| Natalie Grover | Medical Oncology | Chapel Hill, NC | $2,683 | $0 |
| Karen Ballen, Md, MD | Internal Medicine | Falls Church, VA | $2,545 | $0 |
| Michelle Hudspeth, M.d, M.D | Pediatric Hematology-Oncology | Charleston, SC | $2,496 | $0 |
| Dr. Hemant Murthy, M.d, M.D | Hematology & Oncology | Jacksonville, FL | $2,493 | $0 |
| Dr. Adetola Kassim, Md, MD | Medical Oncology | Nashville, TN | $2,371 | $0 |
| Dr. Leland Metheny, M.d, M.D | Hematology | Cleveland, OH | $2,357 | $0 |
| Dr. Mhd Monzr Al Malki, M.d, M.D | Internal Medicine | Duarte, CA | $2,247 | $0 |
| Richaele Nichiporenko, Dnp, Arnp, Fnp-Bc, DNP, ARNP, FNP-BC | Family | Boca Raton, FL | $2,208 | $0 |
| Edwin Pascal Alyea, M.d, M.D | Hematology & Oncology | Boston, MA | $2,200 | $0 |
| Shannon Smiley, M.d, M.D | Internal Medicine | Anchorage, AK | $2,175 | $0 |
| Dr. Sayed Mehdi Hamadani, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $2,158 | $0 |
| Mark Juckett, Md, MD | Internal Medicine | Minneapolis, MN | $2,136 | $0 |
| Krishna Komanduri, M.d, M.D | Hematology & Oncology | Miami, FL | $2,043 | $0 |
| Adrianna Vlachos, Md, MD | Pediatric Hematology-Oncology | St Petersburg, FL | $2,000 | $0 |
| Dr. Thomas Spitzer, Md, MD | Internal Medicine | Boston, MA | $2,000 | $0 |
| Dr. Shukaib Arslan, M.d, M.D | Hematology & Oncology | Dallas, TX | $2,000 | $0 |
| Dr. Jean Yared, M.d, M.D | Hematology & Oncology | Baltimore, MD | $1,988 | $0 |
Ad
Payment Categories
- Food & Beverage $128,225
- Consulting $653,510
- Travel & Lodging $594,712
- Research $13.9M
About National Marrow Donor Program
National Marrow Donor Program has made $25.6M in payments to 276 healthcare providers, recorded across 5,232 transactions in the CMS Open Payments database. In 2024, the company paid $10.2M.
Payments were distributed across 39 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($211,757 to 33 doctors).
Payment categories include: Food & Beverage ($128,225), Consulting ($653,510), Research ($13.9M), Travel & Lodging ($594,712).